Epistemis

Pramipexole

  • Non-Ergotic Dopamine Agonist / Selective D3 Receptor

Synthetic agonist agent with high dopaminergic selectivity, characterized by high stabilizing efficacy and compulsive psychiatric adverse effects.

Mechanism

Chemical and Commercial Profile

Common trade names: Mirapexin, Oprymea, Pramipexol Kern Pharma.
Group: Antiparkinsonian, non-ergot synthetic dopamine agonist.

Mechanism of Action

Pramipexole acts by **direct stimulation of postsynaptic dopamine receptors** in the striatum, without requiring synthesis, storage or presynaptic release. It presents an extreme intrinsic affinity for the D2 and D3 receptor subfamily, with a binding selectivity **7 times higher for the D3** receptor (located abundantly in the mesolimbic areas and the ventral striatum). This explains its associated moderate antidepressant efficacy.

Pharmacokinetics

Pharmacokinetics

  • Absorption: Rapid and almost complete orally; 90% bioavailability. The plasma peak is reached after 2 hours.
  • Distribution: Very low binding to plasma proteins (<15%). Large distribution volume of 7 L/kg. It quickly crosses the blood-brain barrier.
  • Metabolism: Absent in the liver. It does not present interactions with the cytochrome system.
  • Excretion: Renal predominantly by active tubular secretion and glomerular filtration (90%) as unchanged drug.
  • Half-life (t1/2): 8 hours in healthy adults; It is prolonged to >12 hours in the elderly due to the physiological decrease in renal clearance.

Indicators and dose

Indications

  • Treatment of Idiopathic Parkinson's Disease (as initial monotherapy to delay the need for levodopa, or in adjuvant combination to reduce motor fluctuations).
  • Symptomatic treatment of moderate to severe Restless Legs Syndrome (RLS).

Dosage and Settings

  • Progressive Start Schedule (Immediate Release Tablets):
    • Week 1: 0.088 mg three times a day (0.264 mg/day total).
    • Week 2: 0.18 mg three times a day (0.54 mg/day).
    • Week 3: 0.35 mg three times a day (1.1 mg/day).
  • Usual therapeutic range: 1.5-4.5 mg/day (divided into three doses or in a single dose using prolonged-release tablets).
  • Analytical adjustment in Renal Failure:
    • ClCr [20-50 ml/min]: Reduce the theoretical dose and space the titration by 50% of the standard (start with 0.088 mg twice a day, limit of 2.25 mg/day).
    • ClCr < 20 ml/min: Absolutely contraindicated.

Security

Contraindications

  • Hypersensitivity to the active ingredient.
  • Moderate to severe renal failure (ClCr < 20 ml/min).

Adverse Effects (ADR)

Psychiatric Alert · Impulse Control Disorder

Pramipexole associates a ~15-20% risk of inducing **impulse control disorders (ICDs)** due to massive stimulation of mesolimbic D3 receptors. It presents with compulsive hypersexuality, pathological gambling addiction (gambling addiction), compulsive shopping, nighttime binge eating and punding (endless repetitive motor behaviors). It requires actively questioning the patient and family; It is reversible after gradually stopping the drug.

  • CNS: Sudden sleep attacks (rapid-onset episodes of drowsiness during daily activities such as driving, without prior warning signs), visual hallucinations, confusion, dizziness, headache, sleep-onset insomnia (early onset).
  • Cardiovascular: Symmetric orthostatic hypotension, postural dizziness.
  • General: Nausea of central dopaminergic origin, moderate bilateral symmetrical peripheral edema of the lower extremities.

Clinical Interactions

  • Cimetidine and Ranitidine: These drugs block the secretion of organic cations in the proximal renal tubule, decreasing the renal clearance of pramipexole by 30% and increasing the risk of hallucinations.
  • Dopaminergic Antagonists: Neuroleptics or metoclopramide competitively block striatal receptors, nullifying the clinical efficacy of pramipexole.

Pregnancy and Breastfeeding

FDA Category: C. Very limited human data; associates decreased embryonic growth in animals. Breastfeeding: Absolutely contraindicated. Like other dopaminergic drugs, it potently inhibits pituitary prolactin release reflexively, suppressing lactation, in addition to being excreted in milk.

Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.

PreviousLevodopa / Carbidopa (and Benserazide)
System
Antiepileptics and Antiparkinsonians
Cluster
Non-Ergotic Dopamine Agonist / Selective D3 Receptor
Download Epistemis